Biotech News

Vaccinex Reports 2025 Annual Financial Results

Vaccinex (VCNX)Vaccinex2026-06-25 13:46 ESTEarnings

ROCHESTER, N.Y., April 29, 2026 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (OTCMKTS:VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in Alzheimer’s, Huntington’s disease, and cancer today released financial results for the year ended December 31, 2025.

Open original release

Related news

VCNXVaccinex2026-06-25 13:46 EST

Vaccinex Reports New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (CTAD) Conference in Madrid, Spain

VCNXVaccinex2026-06-25 13:46 EST

Vaccinex Reports Improved Immunity Correlating with Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual Meeting

VCNXVaccinex2026-06-25 13:46 EST

Vaccinex Provides Update on ActivMAb® Platform: Multiple Project Deals and Presentation at SITC

VCNXVaccinex2026-06-25 13:46 EST

Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update

VCNXVaccinex2026-06-25 13:46 EST

Vaccinex Announces Receipt of Delisting Notification from Nasdaq

VCNXVaccinex2026-06-25 13:46 EST

Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market

VCNXVaccinex2026-06-25 13:46 EST

Vaccinex to Report Promising New Clinical Data Revealing Pepinemab’s Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR)

VCNXVaccinex2026-06-25 13:46 EST

Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting

VCNXVaccinex2026-06-25 13:46 EST

Vaccinex, Inc. Announces $60 million Agreement to Finance a Phase 2b clinical trial of pepinemab to treat Alzheimer’s Disease

NRSNNeuroSense Therapeutics2026-06-25 13:46 EST

NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease

View all latest news

Vaccinex

Vaccinex is an infectious-disease or vaccine company focused on immunity-driven programs where clinical, regulatory, and demand cycles can shift quickly.

Recent company news

VCNXVaccinex2026-06-26 00:18 EST

Vaccinex Reports New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (CTAD) Conference in Madrid, Spain

VCNXVaccinex2026-06-26 00:18 EST

Vaccinex Reports Improved Immunity Correlating with Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual Meeting

VCNXVaccinex2026-06-26 00:18 EST

Vaccinex Provides Update on ActivMAb® Platform: Multiple Project Deals and Presentation at SITC

VCNXVaccinex2026-06-26 00:18 EST

Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update

VCNXVaccinex2026-06-26 00:18 EST

Vaccinex Announces Receipt of Delisting Notification from Nasdaq

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States